bullish
BeiGene: Novartis Grabs Tislelizumab Rights
260 Views13 Jan 2021 02:26
BeiGene's deal with Novartis for PD-1 tislelizumab validates its competitive position, and marks a rising trend of Chinese companies licensing products to MNCs for a leveraged impact on valuations.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Kemp Dolliver, CFA
Founder
Price Chart(Sign Up to Access)
- BeiGene: Novartis Grabs Tislelizumab Rights13 Jan 2021
- BeiGene: Cancer Treatment in China--The Underestimated Opportunity10 Jan 2021
- Jacobio Pharma IPO Initiation: Drugging the Undruggable05 Dec 2020
- Autonomous Driving- Are We There Yet?20 Mar 2018
x